Beta blockers in hypertension
- PMID: 6139008
- DOI: 10.1016/0002-9149(83)90637-9
Beta blockers in hypertension
Abstract
Beta-adrenoceptor antagonists are effective in the management of patients with mild-to-moderate hypertension. Noncardioselective agents, cardioselective agents and beta blockers with intrinsic sympathomimetic activity (ISA) are equally effective, provided they are used in equipotent doses. Beta blockers can be used as first-line therapy in the management of hypertension and can be safely combined with diuretics, vasodilators, or both, for a better control of blood pressure. The exact mechanism by which beta blockers decrease blood pressure remains speculative, but they all reduce cardiac output during long-term therapy; drugs with ISA lower cardiac output and heart rate less than do drugs without ISA. Pharmacokinetic properties of beta blockers differ widely; drugs metabolized by the liver have shorter plasma half-lives than drugs primarily excreted by the kidneys. Although many of the side effects of various beta blockers are similar, differences in water and lipid solubility account for a higher incidence of central nervous system side effects with lipid-soluble drugs (such as propranolol and metoprolol) than with hydrophilic drugs (such as atenolol and timolol). The incidence of cold extremities has been reported to be less with drugs with ISA, and the incidence of bronchospasm less with cardioselective drugs. In the management of uncomplicated mild-to-moderate hypertension, all beta blockers are equally effective and produce less troublesome side effects than alternative antihypertensive agents. For effective therapy beta blockers can be used in 2 divided daily doses or even once daily.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.Postgrad Med J. 1983;59 Suppl 3(689):140-58. Postgrad Med J. 1983. PMID: 6139800 Free PMC article. Review.
-
Haemodynamic consequences of intrinsic sympathomimetic activity and cardioselectivity in beta-blocker therapy for hypertension.Eur Heart J. 1983 Jul;4 Suppl D:31-41. doi: 10.1093/eurheartj/4.suppl_d.31. Eur Heart J. 1983. PMID: 6137381
-
The additional properties of beta adrenoceptor blocking drugs.J Cardiovasc Pharmacol. 1986;8 Suppl 4:S1-15. doi: 10.1097/00005344-198608004-00002. J Cardiovasc Pharmacol. 1986. PMID: 2427833 Review.
-
Use of beta-adrenoceptor blocking drugs in hyperthyroidism.Drugs. 1984 May;27(5):425-46. doi: 10.2165/00003495-198427050-00003. Drugs. 1984. PMID: 6144501 Review.
-
Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol.Eur Heart J. 1983 Jul;4 Suppl D:1-12. doi: 10.1093/eurheartj/4.suppl_d.1. Eur Heart J. 1983. PMID: 6137366
Cited by
-
Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.Cardiovasc Drugs Ther. 1988 Jul;2(2):211-8. doi: 10.1007/BF00051236. Cardiovasc Drugs Ther. 1988. PMID: 2908720 Clinical Trial.
-
Effect of acute administration of propranolol and atenolol on baroreflex function in normal man.Eur J Clin Pharmacol. 1988;35(6):607-12. doi: 10.1007/BF00637596. Eur J Clin Pharmacol. 1988. PMID: 3148471 Clinical Trial.
-
Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.Eur J Clin Pharmacol. 1988;34(6):605-11. doi: 10.1007/BF00615225. Eur J Clin Pharmacol. 1988. PMID: 3169112 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical